Skip to main content
. Author manuscript; available in PMC: 2015 Apr 2.
Published in final edited form as: Lancet Oncol. 2014 Feb 7;15(3):323–332. doi: 10.1016/S1470-2045(14)70012-9

Table 5.

Selected adverse events in patients treated with vemurafenib, by mutational status

BRAFV600E (n=295) BRAFV600K (n=33)
Total patients with ≥1 adverse event 294 (100%) 33 (100%)
Arthralgia 171 (58%) 13 (39%)
Rash 123 (42%) 13 (39%)
Fatigue 133 (45%) 18 (55%)
Photosensitivity 120 (41%) 12 (36%)
Cutaneous squamous-cell carcinoma 57 (19%) 8 (24%)
Keratoacanthoma 29 (10%) 7 (21%)
Skin papilloma 85 (29%) 9 (27%)
Nausea 117 (40%) 8 (24%)

Data are number of patients (%).